Effect of Zuranolone vs Placebo in Postpartum Depression: A Randomized Clinical Trial

RCT (n=151) of this neuroactive steroid GABAA receptor–positive allosteric modulator found it improved core symptoms of depression as measured by HAMD-17 scores (−17.8 vs −13.6; p = 0.003) and was generally well tolerated, supporting further development for postpartum depression

Source:

JAMA Psychiatry